Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: Application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009)

Diagnostic Microbiology and Infectious Disease

Volumn 69, Issue 1, 2011, Pages 45-50

  Pfaller, Michael A ^a,b   Castanheira, Mariana ^a   Messer, Shawn A ^a   Moet, Gary J ^a   Jones, Ronald N ^a,c  

^a JMI LABORATORIES   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antifungal agents; Breakpoints; Candida spp.; CLSI; Resistance; SENTRY

Indexed keywords

ANIDULAFUNGIN; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLUS FUMIGATUS; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; DRUG POTENCY; FUNGUS ISOLATION; FUNGUS MUTATION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; ASPERGILLUS FUMIGATUS; CANDIDA; CRYPTOCOCCUS NEOFORMANS; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOSES; TRIAZOLES;

EID: 78649936372     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2010.08.013     Document Type: Article

References (40)

1. Alexander B.D., Pfaller M.A. Contemporary tools for the diagnosis and management of invasive mycoses. Clin. Infect. Dis. 2006, 43:S15-S27.
2. Arnold H.M., Micek S.T., Shorr A.F., Zilberberg M.D., Labelle A.J., Kothari S., Kollef M.H. Hospital resource utilization and costs of inappropriate treatment of candidemia. Pharmacotherapy 2010, 30:361-368.
3. Baddley J.W., Marr K.A., Andes D.R., Walsh T.J., Kauffman C.A., Kontoyiannis D.P., Ito J.I., Balajee S.A., Pappas P.G., Moser S.A. Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network. J. Clin. Microbiol. 2009, 47:3271-3275.
4. Bicanic T., Harrison T., Niepieklo A., Dyakopu N., Meintjes G. Symptomatic relapse of HIV-associated Cryptococcal meningitis after initial fluconazole monotherapy: the role of fluconazole resistance and immune reconstitution. Clin. Infect. Dis. 2006, 43:1069-1073.
5. Castanheira M., Woosley L.N., Pfaller M.A., Diekema D.J., Messer S.A., Jones R.N. Low prevalence of fks1 hotspot 1 mutations in a worldwide collection of Candida spp. Antimicrob. Agents Chemother. 2010, 54:2655-2659.
6. Chapeland-Leclerc F., Hennequin C., Papon N., Noel T., Girard A., Socie G., Ribaud P., Lacroix C. Acquisition of flucytosine, azole, and caspofungin resistance in Candida glabrata bloodstream isolates serially obtained from a hematopoietic stem cell transplant recipient. Antimicrob. Agents Chemother. 2010, 54:1360-1362.
7. Clinical and Laboratory Standards Institute (CLSI) Reference method for broth dilution antifungal susceptibility testing of yeasts: third edition (M27-A3) 2008, CLSI, Wayne, PA.
8. Clinical and Laboratory Standards Institute (CLSI) Reference method for broth dilution antifungal susceptibility testing of yeasts: third informational supplement (M27-S3) 2008, CLSI, Wayne, PA.
9. Clinical and Laboratory Standards Institute (CLSI) Reference method for broth dilution antifungal susceptibility testing of filamentous fungi: second edition (M38-A2) 2008, CLSI, Wayne, PA.
10. Espinel-Ingroff A., Canton E., Fothergill A., Johnson E.M., Pelaez T., Pfaller M.A., Rinaldi M.G., Turnidge J.D. Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). J. Clin. Microbiol. 2010, 48:3251-3257.
11. Falagas M.E., Apostolou K.E., Pappas V.D. Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies. Eur. J. Clin. Microbiol. Infect. Dis. 2006, 25:419-425.
12. Fishman J.A., Gonzalez R.G., Branda J.A. Case records of the Massachusetts General Hospital. Case 11-2008. A 45-year-old man with changes in mental status after liver transplantation. N. Engl. J. Med. 2008, 358:1604-1613.
13. Garcia-Effron G., Park S., Perlin D.S. Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. Antimicrob. Agents Chemother. 2009, 53:112-122.
14. Garey K.W., Turpin R.S., Bearden D.T., Pai M.P., Suda K.J. Economic analysis of inadequate fluconazole therapy in non-neutropenic patients with Candidaemia: a multi-institutional study. Int. J. Antimicrob. Agents 2007, 29:557-562.
15. Hazen K.C., Howell S.A. Candida, Cryptococcus, and other yeasts of medical importance. Manual of Clinical Microbiology 2007, 1762-1788. ASM Press, Washington, DC. P.R. Murray, E.J. Baron, J.H. Jorgensen, M.L. Landry, M.A. Pfaller (Eds.).
16. Howard S.J., Cerar D., Anderson M.J., Albarrag A., Fisher M.C., Pasqualotto A.C., Laverdiere M., Arendrup M.C., Perlin D.S., Denning D.W. Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg. Infect. Dis. 2009, 15:1068-1076.
17. Labelle A.J., Micek S.T., Roubinian N., Kollef M.H. Treatment-related risk factors for hospital mortality in Candida bloodstream infections. Crit. Care Med. 2008, 36:2967-2972.
18. Leaw S.N., Chang H.C., Sun H.F., Barton R., Bouchara J.P., Chang T.C. Identification of medically important yeast species by sequence analysis of the internal transcribed spacer regions. J. Clin. Microbiol. 2006, 44:693-699.
19. Messer S.A., Kirby J.T., Sader H.S., Fritsche T.R., Jones R.N. Initial results from a longitudinal international surveillance programme for anidulafungin (2003). J. Antimicrob. Chemother. 2004, 54:1051-1056.
20. Messer S.A., Moet G.J., Kirby J.T., Jones R.N. Activity of contemporary antifungal agents, including the novel echinocandin anidulafungin, tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2006 to 2007). J. Clin. Microbiol. 2009, 47:1942-1946.
21. Messer S.A., Jones R.N., Moet G.J., Kirby J.T., Castanheira M. Anidulafungin potency compared to nine other antifungal agents tested against Candida spp. Cryptococcus spp., and Aspergillus spp: results from the Global SENTRY Antimicrobial Surveillance Program (2008). J. Clin. Microbiol. 2010, 48:2984-2987.
22. Mirza S.A., Phelan M., Rimland D., Graviss E., Hamill R., Brandt M.E., Gardner T., Sattah M., de Leon G.P., Baughman W., Hajjeh R.A. The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992-2000. Clin. Infect. Dis. 2003, 36:789-794.
23. Nimi K., Monk B.C., Hirai A., Hatakenaka K., Umeyama T., Lamping E., Maki K., Tanabe K., Kamimura T., Ikeda F., Uehara Y., Kano R., Hasegawa A., Cannon R.D., Niimi M. Clinically significant micafungin resistance in Candida albicans involves modification of a glucan synthase catalytic subunit GSC1 (FKS1) allele followed by loss of heterozygosity. J. Antimicrob. Chemother. 2010, 65:842-852.
24. Pfaller M.A., Diekema D.J. Epidemiology of invasive candidiasis: a persistent public health problem. Clin. Microbiol. Rev. 2007, 20:133-163.
25. Pfaller M.A., Diekema D.J. Epidemiology of invasive mycoses in North America. Crit. Rev. Microbiol. 2010, 36:1-53.
26. Pfaller M.A., Jones R.N., Doern G.V., Fluit A.C., Verhoef J., Sader H.S., Messer S.A., Houston A., Coffman S., Hollis R.J. International surveillance of blood stream infections due to Candida species in the European SENTRY Program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. SENTRY Participant Group (Europe). Diagn. Microbiol. Infect. Dis. 1999, 35:19-25.
27. Pfaller M.A., Diekema D.J., Jones R.N., Messer S.A., Hollis R.J. Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. J. Clin. Microbiol. 2002, 40:852-856.
28. Pfaller M.A., Diekema D.J., Rex J.H., Espinel-Ingroff A., Johnson E.M., Andes D., Chaturvedi V., Ghannoum M.A., Odds F.C., Rinaldi M.G., Sheehan D.J., Troke P., Walsh T.J., Warnock D.W. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J. Clin. Microbiol. 2006, 44:819-826.
29. Pfaller M.A., Pappas P.G., Wingard J.R. Invasive fungal pathogens: current epidemiological trends. Clin. Infect. Dis. 2006, 43:S3-S14.
30. Pfaller M.A., Boyken L., Hollis R.J., Kroeger J., Messer S.A., Tendolkar S., Diekema D.J. In vitro susceptibility of clinical isolates of Aspergillus spp. to anidulafungin, caspofungin, and micafungin: a head-to-head comparison using the CLSI M38-A2 broth microdilution method. J. Clin. Microbiol. 2009, 47:3323-3325.
31. Pfaller M.A., Messer S.A., Hollis R.J., Boyken L., Tendolkar S., Kroeger J., Diekema D.J. Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location in the United States in 2001 to 2007. J. Clin. Microbiol. 2009, 47:3185-3190.
32. Pfaller M.A., Andes D., Diekema D.J., Espinel-Ingroff A., Sheehan D., for the CLSI Subcommittee for Antifungal Testing Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist. Updat. 2010, (In press).
33. Pfaller M.A., Castanheira M., Diekema D.J., Messer S.A., Moet G.J., Jones R.N. Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest methods with the CLSI broth microdilution method for echinocandin susceptibility testing of Candida species. J. Clin. Microbiol. 2010, 48:1592-1599.
34. Pfaller M.A., Diekema D.J., Andes D., Arendrup M.C., Brown S.D., Motyl M., Perlin D.S., Testing TCSfA Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist. Updat. 2010, (In press).
35. Pfeiffer C.D., Garcia-Effron G., Zaas A.K., Perfect J.R., Perlin D.S., Alexander B.D. Breakthrough invasive candidiasis on micafungin. J. Clin. Microbiol. 2010, 48:2373-2380.
36. Procop G.W., Roberts G.D. Emerging fungal diseases: the importance of the host. Clin. Lab. Med. 2004, 24:691-719.
37. Rodriguez-Tudela J.L., Alcazar-Fuoli L., Mellado E., Alastruey-Izquierdo A., Monzon A., Cuenca-Estrella M. Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus. Antimicrob. Agents Chemother. 2008, 52:2468-2472.
38. Sun H.Y., Singh N. Characterisation of breakthrough invasive mycoses in echinocandin recipients: an evidence-based review. Int. J. Antimicrob. Agents 2010, 35:211-218.
39. Verweij P.E., Brandt M.E. Asperigillus, Fusarium, and other opportunisitic moniliaceous fungi. Manual of Clinical Microbiology 2007, 1802-1838. American Society for Microbiology, Washington, DC. M.A. Pfaller (Ed.).
40. Zilberberg M.D., Shorr A.F., Kollef M.H. Secular trends in candidemia-related hospitalization in the United States, 2000-2005. Infect. Control Hosp. Epidemiol. 2008, 29:978-980.